Loading
A phase 2 trial of Iniparib, Gemcitabine and Carboplatin in Breast cancer, run by Sanofi, completed.
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer is a phase 2 interventional study registered as NCT01045304 by Sanofi, with 163 participants recorded, started 2010-02 and reaching its primary completion in 2011-03. Interventions recorded: Iniparib, Gemcitabine, Carboplatin. Conditions recorded: Breast Cancer, Metastatic.
Linked to the drug Iniparib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iniparib, Sanofi, Gemcitabine, Carboplatin and the tag pipeline.
Shares Iniparib, Sanofi, Breast cancer (all types) and the tag pipeline.
Shares Sanofi, Gemcitabine, Breast cancer (all types) and the tag pipeline.
Shares Sanofi, Carboplatin and the tag pipeline.
Shares Gemcitabine, Carboplatin and the tag pipeline.
Shares Gemcitabine, Carboplatin and the tag pipeline.
Shares Carboplatin, Breast cancer (all types) and the tag pipeline.
Shares Gemcitabine, Carboplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/